RECENT COMMENTS

Kathy Redmond: Readers may have noticed that ESO has deleted a number of comments on this article. This is because [...]   »Read more

Pongsri (Sex and cancer): I teach body image and sexuality in cancer survivors for specialty 4 month cancer nurse program. Thi [...]   »Read more

DR Jennifer L Scott (Sex and cancer): Togehter with my colleague Prof Karen Kayser I have published a review of RCT of interventions to en [...]   »Read more

Dr O. Abimbola Oluwatosin (Sex and cancer): I teach sexuality in Nursing at post graduate level. This article is very useful and will be added t [...]   »Read more

Dr. Yannis Vassiliou (political oncology): A great article, well done! I was deeply disappointed by the comments of the Turkish colleagues, wh [...]   »Read more

 

Article type: Drug Watch

Keywords: Personal genetic signatures, personalised therapy, MammaPrint, MINDACT, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Bringing personalised cancer treatments to the people

Personal genetic signatures may help assess a person’s risk of getting cancer, predict risk of recurrence, or identify the best treatment for them. At a Meet the Experts session, nine ASCO luminaries explained to press and public why it is crucial to invest in this area of research.

» Elizabeth DeVita-Raeburn

To read the complete article please click on the pdf icon

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.